Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-12
2005-07-12
Fay, Zohreh (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S292000, C514S912000
Reexamination Certificate
active
06916824
ABSTRACT:
Water-soluble, cell permeable aldose reductase inhibitors are presented. These compounds prevent the effects of galactosemia in patients. The compounds prevent both the accumulation of polyols and the change in levels of protein kinase C gamma observed during diabetes and galactosemia.
REFERENCES:
patent: 5958970 (1999-09-01), Hua et al.
Aiello et al., (Mar. 1999), “Amelioration of Abnormal Retinal Memodynamics by a Protein Kinase C β-Selective Inhibitor (LY33531) in Patients with Diabetes: Results of a Phase I Safety and Pharmacodynamic Clinical Trial,”IVOS40:S192.
Cervera et al., (1990), “4-Amino-6-Methyl-2H-Pyran-2-One. Preparation and Reactions with Aromatic Aldehydes,”Tetrahedron46:7885-7892.
Dess, D.B. and Martin, J.C. (1983), “Readily accessible 12-I-51Oxidant for the Conversion of Primary and Secondary Alcohols to Aldehydes and Ketones,”J. Org. Chem.48:4155-4156.
Hua et al., (1997), “(5aS,7S)-7-Isopropenyl-3--methyl-5a,6,8,9-tetrahedro-1H,7H-pyrano[4,3-b][1]benzopyran-1-one,”Acta CrystC53:1995-1997.
Hua et al., (1997), A One-Pot Condensation of Pyrones and Enals. Synthesis of 1H,7H-5a,6,8,9-Tetrahydro-1-oxopyrano[4,3-b]benzopyrans.J. Org. Chem.62:6888-6896.
Urzhumtsev et al., (1997), “A ‘specificity’ pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil,”Structure5:601-612.
Vedejs et al., (1978), “Transition-Metal Peroxide Reaction. Synthesis of α-Hydroxycarbonyl Compounds from Enolates,”J. Org. Chem.43:188-196.
Williamson et al., (Mar. 1999), “Ocular and Cerebral Vascular Dysfunction Induced by Diabetes and by LY33531, a β-Selective Inhibitor of Protein Kinase C,”IOVS40:S369.
Brightman Alan
Fenwick Bradley W.
Hua Duy H.
Takemoto Dolores J.
Fay Zohreh
Greenlee Winner and Sullivan P.C.
Kansas State University Research Foundation
LandOfFree
Methods of treating cataracts and diabetic retinopathy with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating cataracts and diabetic retinopathy with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating cataracts and diabetic retinopathy with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3369845